Poster

Bile acids are commonly extracted from complex biological samples with methanol -based extraction procedures. However, with these simple extraction procedures, numerous reports have found that accumulating lipids on the analytical column interferes with LC/MS analyses of bile acids. In our experience, these adverse effects included increasing column backpressure, retention time drift and peak shape broadening over multiple injections. In lieu of employing an alternative offline solid -phase extraction (SPE) cleanup, we investigated several column chemistries and mobile phase combinations in conjunction with the simple protein precipitation extraction.

Download the poster, presented at ASMS 2026, to learn how Aliri approached the quantitation of 20 bile acids in human serum and urine.

Antibody-drug conjugates achieve therapeutic activity only when payload delivery, target accessibility, and microenvironmental readiness align within tumor tissue. Conventional biomarkers capture isolated components of this biology but fail to resolve the spatial coordination that ultimately governs pharmacodynamic activity.

To address this gap, we developed a translational spatial PK/PD framework integrating MSI, spatial proteomics/transcriptomics, and multiplex tissue imaging to spatially interpret coordinated ADC activity within solid tumors

Download the poster, recently presented at EACR 2026 in Budapest, Hungary to learn more.

Spatial biology technologies are transforming translational oncology by enabling high-resolution characterization of tumor–immune ecosystems. However, the clinical utility of spatial biomarkers remains limited by a lack of standardized, qualified panels capable of generating reproducible and decision-enabling data across studies. To address this gap, we developed a framework for the qualification of translational spatial biomarker panels designed to support drug development and clinical trial biomarker strategies. By integrating multiplex immunofluorescence, digital pathology, and AI-assisted image analysis, our objective was to establish reproducible workflows capable of generating biologically relevant and analytically robust spatial biomarkers suitable for translational oncology applications.

Download the poster, recently presented at EACR 2026 in Budapest, Hungary to learn more.

Precision medicine requires technologies capable of capturing both molecular heterogeneity and tissue architecture. Unlike conventional bulk approaches, spatial multi-omics preserves tissue context, enabling the characterization of genes, proteins, metabolites, and cell–cell interactions within their native environment. Combined with AI-driven image analysis and multimodal data integration, spatial multi-omics provides a powerful framework for biomarker discovery, patient stratification, and treatment response prediction.

To demonstrate the potential of AI-enabled spatial multi-omics for precision medicine, we applied an established machine learning framework to identify treatment-associated molecular signatures in cervical cancer using integrated proteomic, transcriptomic, and metabolomic data.

Download our poster, recently presented at AI in Oncology Paris to learn more.

Historically, LC-MS/MS focused on synthetic drug pharmacokinetics. However, improved sensitivity now allows the analysis of endogenous biomarkers (lipids, proteins, etc.) previously reserved for Ligand Binding Assays (LBA). A primary challenge in biomarker bioanalysis is that these compounds are endogenous to biological matrices, and the matrix could present challenging physicochemical properties. Unlike conventional drug testing, there is no true blank matrix available to build calibration standards. To quantify these levels accurately, researchers must develop a surrogate matrix that mimics the behavior of authentic patient samples without the background interference of the natural analyte. Selecting and validating this surrogate is the most critical step in establishing a reliable LC-MS/MS method for any naturally occurring compound.

Download our poster, recently presented at WRIB 2026 to learn more.

In this scientific poster recently presented at EBF Open Symposium, we investigated the biodistribution and potential toxicity of lipid nanoparticles (LNP1 and LPN2), which are crucial carriers for mRNA-based treatments after administration to male and female mice, analyzing their distribution in whole-body carcasses and specific organs using MALDI-MSI.

Download our poster to learn more.

In this scientific poster recently presented at EBF Open Symposium, we investigated the biodistribution and potential toxicity of lipid nanoparticles (LNP1 and LPN2), which are crucial carriers for mRNA-based treatments after administration to male and female mice, analyzing their distribution in whole-body carcasses and specific organs using MALDI-MSI.

Download our poster to learn more.

This study aims to optimize and validate a qPCR workflow for the reproducible and sensitive quantification of immune checkpoint transcripts (PD-1,PD-L1, CTLA-4) in FFPE lung cancer tissues. By refining tissue preparation, RNA input, and assay conditions, we establish a robust method for detecting gene expression across a broad dynamic range, enabling reliable assessment of immunotherapy response and supporting biomarker-driven patient stratification.​

Download our poster to learn more.

MALT1 is a key mediator of NF-κB signaling and an emerging therapeutic target in B-cell malignancies and autoimmune diseases. SGR-1505, a potent MALT1 inhibitor, is being clinically evaluated for its therapeutic potential. In this study, we developed and validated a reliable and high-throughput LC-MS/MS method for the quantitation of SGR-1505 in human plasma (K₂EDTA) to support clinical pharmacokinetic studies. This work exemplifies the critical role of CRO-led bioanalysis in bridging early discovery and clinical development of emerging therapeutics.​

Download our poster to learn more.

Bioanalytical methods are needed to analyze protein conjugated antisense oligonucleotides (POCs) to accurately quantify the active antisense oligonucleotide (ASO) payloads, assess its pharmacokinetics and biodistribution in plasma and tissues, and ensure patient safety by evaluating potential immunogenicity and toxicity. Because the conjugate, the free ASO, and the linked ASO fragment can all be present, specialized techniques are required to differentiate and quantify these components, which is essential for supporting the development of these complex biotherapeutics. The unique properties of POCs present significant analytical challenges that necessitate specialized methods.

We set out to develop a methodology for quantifying total ASO in POCs that could be universally applied across similar POCs. The
study compared mass spectrometry and fluorescence detection platforms to determine optimal sensitivity, selectivity,
and adaptability. Additionally, it aimed to establish a single extraction method suitable for both plasma and tissue
analysis.

Download our poster to learn more.